NASDAQ · BCRX
Healthcare · Biotechnology
$8.52
Up+$0.15 (+1.79%)
Updated Oct 30, 2026, 11:47 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BCRX
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
BCRX closed at $8.52 after 21 trading sessions, up 4.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $8.45 | $8.56 | $8.39 | $8.52 | 4.52M |
| Oct 28, 2026 | $8.05 | $8.445 | $8.005 | $8.37 | 3.94M |
| Oct 27, 2026 | $7.925 | $8.12 | $7.81 | $8.10 | 8.75M |
| Oct 26, 2026 | $7.69 | $8.00 | $7.66 | $7.88 | 4.38M |
| Oct 23, 2026 | $7.71 | $7.7642 | $7.52 | $7.65 | 2.75M |
| Oct 22, 2026 | $7.78 | $7.88 | $7.66 | $7.78 | 4.81M |
| Oct 21, 2026 | $8.04 | $8.05 | $7.73 | $7.75 | 5.03M |
| Oct 20, 2026 | $8.11 | $8.13 | $7.84 | $7.94 | 8.46M |
| Oct 19, 2026 | $7.77 | $8.09 | $7.77 | $8.07 | 9.77M |
| Oct 16, 2026 | $7.96 | $8.015 | $7.74 | $7.79 | 4.43M |
| Oct 15, 2026 | $8.105 | $8.24 | $7.945 | $8.02 | 4.5M |
| Oct 14, 2026 | $8.02 | $8.18 | $7.97 | $8.05 | 5.65M |
| Oct 13, 2026 | $8.22 | $8.315 | $8.06 | $8.07 | 3.04M |
| Oct 12, 2026 | $8.49 | $8.55 | $8.24 | $8.36 | 3.47M |
| Oct 9, 2026 | $8.27 | $8.595 | $8.27 | $8.55 | 2.31M |
| Oct 8, 2026 | $8.36 | $8.40 | $8.13 | $8.29 | 5.12M |
| Oct 7, 2026 | $7.91 | $8.425 | $7.86 | $8.40 | 5.12M |
| Oct 6, 2026 | $8.15 | $8.15 | $7.87 | $7.95 | 3.94M |
| Oct 5, 2026 | $8.17 | $8.25 | $7.915 | $8.10 | 4.71M |
| Oct 2, 2026 | $8.12 | $8.20 | $7.92 | $8.17 | 6.15M |
| Oct 1, 2026 | $8.30 | $8.38 | $8.065 | $8.12 | 6.87M |
The latest Smart Investors Daily articles mentioning BCRX.
Company
Market Activity
Research & News
BCRX research
Company profile and research snapshot.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2026 | JP Morgan | Neutral | — |
| Sep 10, 2026 | RBC Capital | Sector Perform | — |
| Sep 8, 2026 | Needham | Buy | — |
| Aug 6, 2026 | Wedbush | Outperform | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.
Yahoo · Oct 21, 2026
RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026. BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update. A live webcast and replay of the call will be available online in the investors section of the company website at www.bioc
Yahoo · Oct 21, 2026
ORLADEYO® (berotralstat) oral pellets 150 mg BioCryst Pharmaceuticals, Inc. —Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE patients aged 2 and above— RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the U.S. Food and Drug Administration (FDA) has approved
Benzinga · Oct 21, 2026
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BCRX.
